E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective is to investigate the safety and tolerability of JNJ-37822681 administered as qd or bid following a dose titration in male and female patients with stable schizophrenia. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives of this study include: • To investigate the plasma pharmacokinetic (PK) profile of JNJ-37822681 administered as once daily (qd) or twice daily (bid) in male and female patients with stable schizophrenia; • To investigate the effect of JNJ-37822681 on plasma prolactin (PRL) levels. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
·Male or female between 18 and 65 years of age, inclusive ·Female subjects must meet one of the following: –postmenopausal (for at least 12 months), –Surgically sterile, (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy) –abstinent (per investigator’s judgement), –if sexually active, be practicing an effective method of birth control (e.g., prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method [e.g., condoms, diaphragm, or cervical cap with spermicidal foam, cream, or gel], male partner sterilization), before entry, and must agree to continue to use the same method of contraception throughout the study. ·Women of childbearing potential must have a negative serum b human chorionic gonadotropin (b hCG) pregnancy test at screening and admission ·Men must agree to use a double barrier method of birth control and to not donate sperm during the study and for 3 months after receiving the last dose of study drug. For men that have been clinically determined to be infertile, this restriction is for 5 days after receiving the last dose of study drug. ·In- or outpatients with schizophrenia stably treated for at least 6 months with antipsychotic monotherapy (£ 200mg/d chlorpromazine equivalent dose) or stable for at least 3 months without drug therapy ·PANSS at screening < 60 ·In the opinion of the investigator and in compliance with local regulations, the subject can be withdrawn from current antipsychotic medication. ·A known (by the site) history of schizophrenia of at least 12 months ·BMI between 18 and 35 kg/m2 inclusive (BMI = weight/height2) ·Willing to be hospitalized during the double-blind treatment period of the study (up to Day 15). ·Willing to adhere to the prohibitions and restrictions specified in this protocol ·Subjects must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study
|
|
E.4 | Principal exclusion criteria |
·A DSM-IV axis I diagnosis other than schizophrenia ·A DSM-IV diagnosis of substance dependence within 6 months prior to screening evaluation (nicotine and caffeine dependence are not exclusionary) ·Any medical condition that could potentially alter the absorption, metabolism, or excretion of the study medication, such as Crohn’s disease, liver disease, or renal disease ·Relevant history of any significant and/or unstable cardiovascular, respiratory, neurologic (including seizures or significant cerebrovascular), renal, hepatic, endocrine, or immunologic diseases ·History of neuroleptic malignant syndrome (NMS) ·Other significant and/or unstable systemic illnesses ·Allergy or hypersensitivity to any known antipsychotic compounds ·Inability to swallow the study medication whole with the aid of water (subjects may not chew, divide, dissolve, or crush the study medication, as this may affect the release profile) ·Exposure to an experimental drug or experimental medical device within 90 days before screening ·Significant risk of suicidal or violent behavior ·Female subjects who are pregnant or breastfeeding ·Alanine aminotransferase or aspartate aminotransferase levels more than 2 times the upper limit of normal ·Other biochemistry, hematology, or urinalysis results that are not within the laboratory’s reference range, and that are deemed by the investigator to be clinically significant ·Use of beta-blockers (if used for any indication other than hypertension and still present at baseline) ·Injection of a depot antipsychotic within 120 days before screening, or use of paliperidone palmitate within 10 months before screening ·Use of fluoxetine or monoamine oxidase inhibitors within 4 weeks before screening ·Use of all other antidepressants, anticonvulsants, or lithium within 2 weeks before baseline ·Received electroconvulsive therapy within 3 months before screening ·Have been involuntarily committed to psychiatric hospitalization ·Any condition that, in the opinion of the investigator, would compromise the well-being of the subject or the study ·Employees of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center, as well as family members of the employees or the investigator.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Evaluate the safety, tolerability, and PK of JNJ-37822681 in patients with schizophrenia in the predicted clinical dose range. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.1.7.1 | Other trial design description |
multi-center, multiple dose titration study |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.3.1 | Comparator description |
|
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 4 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 8 |